Released on March 21, the practice advisory from the American Academy of Neurology advocates for a management approach focused on optimization of medical therapies and exercise over stenting for reducing risk of recurrent events and death in patients with symptomatic intracranial atherosclerotic arterial stenosis
An analysis of data from a prospective stroke registry suggests presence of hypertriglyceridemia was associated with a more than 2-fold increase in risk of MACE among patients with a history of acute stroke or TIA, even with adjustment for baseline LDL-C and statin use.
A new study suggests use of apixaban was associated with a lower rate of rehospitalization for VTE compared with warfarin in patients with VTE requiring extended anticoagulation.
Data show the absolute risk reductions of treatment with statins in terms of all-cause mortality, myocardial infarction, and stroke are modest compared with the relative risk reductions.
Data from Medicare beneficiaries provide insight into the risk of stroke associated with a diagnosis of COVID-19 among older adults, which results suggest peaks within the first 3 days of diagnosis.
A retrospective analysis of 10 years of stroke admissions suggests pediatric stroke patients with LVO who did not undergo thrombectomy were at 6 times greater risk of moderate to severe disability or death than those who underwent thrombectomy.
A retrospective chart review from ISC 2022 details the safety and efficacy of low-dose ticagrelor in clopidogrel-resistant neuroendovascular patients.
An international, retrospective analysis presented at ISC 2022 provides evidence suggesting use of DOACs as a treatment for cerebral venous thrombosis was associated with similar risk of recurrent clots and death as warfarin, but a 65% lower risk of major bleeding.
A meta-analysis presented at ISC 2022 suggests the risk of in-hospital mortality for stroke-related admissions was 42% greater among patients hospitalized during the pandemic compared to prepandemic.
On the first day of International Stroke Conference 2022, the AHA released a scientific statement outlining strategies to optimize in-hospital stroke care.
Analysis of real-world registry data presented at ISC 2022 provide insight into the risk of intracranial hemorrhage with tenecteplase versus alteplase in patients with acute ischemic stroke.
A positive CDI test was more common in patients with suffered an aneurysmal subarachnoid hemorrhage than it was in patients with intracerebral hemorrhage or ischemic stroke.
Bentracimab achieved the predetermined primary endpoint of immediate and sustained reversal of the antiplatelet effects of ticagrelor in the REVERSE-IT trial.
Treatment with statins, nitrates, dihydropyridines, verapamil, and proton-pump inhibitors were predictors of death or ischemic events for patients in the HGFR group.
Data from more than 800 patients with 120 days of continuous heart monitoring data and ischemic stroke provide insight into the timing of arrhythmic episodes and how it can help predict the risk of stroke in patients with CIEDs and atrial fibrillation.
Data show SGLT2 inhibitor therapy, in comparison to GLP-1 RA therapy, was associated with slightly lower risk for myocardial infarction (MI) or stroke in patients with CVD.
Data from a recent analysis suggests patients with diabetes with the lowest levels of insulin resistance had a 40% lower risk of stroke when compared to those with the highest levels.
Abbott announced on September 29 the FDA had granted approval to the Amplatzer Talisman PFO Occluder for use in patients with a PFO at risk of recurrent stroke. This approval was accompanied by the clearance of the Amplatzer Talisman Delivery Sheath.
After presenting at TMIOA's 5th Heart in Diabetes meeting, Silvio Inzucchi, MD, reviews current knowledge related to the effects of diabetes medications on stroke risk.
In his presentation at TMIOA, Dr. Inzucchi referenced several diabetes medications and glucose management methods that resulted in a reduction of stroke risk in patients.
The Amulet IDE Trial is the first trial to offer a head-to-head comparison of the Amplatzer Amulet occluder from Abbot against the Watchman device from Boston Scientific for left atrial appendage occlusion.
Data from the Salt Substitute and Stroke Study suggest switching from regular salt to a salt substitute could reduce the risk of stroke by 14% and investigators believe these results can be applied to patient populations across the world.
Despite increasing detection of atrial fibrillation and rates of anticoagulation, continuous electrocardiographic monitoring with an implantable loop recorder did not significantly reduce risk of stroke in the LOOP study.
An ESC Congress 2021 analysis suggests icosapent ethyl was associated with a 35% reduction in total primary end point events among patients with a history of myocardial infarction prior to enrollment in the REDUCE-IT trial.
The vagus nerve stimulation system is the first of its kind stroke rehabilitation system, after supporting data from the VNS-REHAB trial suggested its efficacy in improving FMA-UE scores.
